The Novel RSV Vaccine: Part 2
05/08/23 • 31 min
Respiratory syncytial virus (RSV) is a leading cause of pneumonia and hospitalizations in children and older adults. A search for a vaccine may finally be over. Join host, Geoff Wall, and guest, Jake Galdo, as they dive into part 2 of a two-part series examining new research on the proposed RSV vaccine.
The GameChanger
RSV, COVID-19, and influenza are major disease burdens on children and older adults. Fortunately, COVID-19 and influenza have widely available vaccines – and maybe soon for RSV. A recent study of the mRNA vaccine in pregnant patients may help newborns.
Show Segments
00:00 - Introductions
02:57 - Recap From Part 1
06:45 - Looking at the MATISSE Study
14:17 - The GameChanger: MATISSE Results
22:27 - Connecting to Practice: Barriers to Applying
31:05 - Closing Remarks
Host
Geoff Wall, PharmD, BCPS, FCCP, BCGP
Professor of Pharmacy Practice, Drake University
Internal Medicine/Critical Care, UnityPoint Health
Guest
Jake Galdo, PharmD, MBA, BCPS, BCGP
Managing Network Facilitator, CPESN Health Equity
CEO, Seguridad
Reference
Kampmann B, Madhi SA, Munjal I, et al. Bivalent Prefusion F Vaccine in Pregnancy to Prevent RSV Illness in Infants. N Engl J Med. 2023 Apr 20;388(16):1451-1464. doi: 10.1056/NEJMoa2216480. Epub 2023 Apr 5. PMID: 37018474.
Pharmacist Members, REDEEM YOUR CPE HERE!
Not a member? Get a Pharmacist Membership & earn CE for GameChangers Podcast episodes! (30 mins/episode)
CE Information
Learning Objectives
Upon successful completion of this knowledge-based activity, participants should be able to:
1. Discuss the MATISSE study in relation to RSV vaccines
2. Describe barriers to applying the information in this study to general populations
0.05 CEU/0.5 Hr
UAN: 0107-0000-23-193-H06-P
Initial release date: 05/08/2023
Expiration date: 05/08/2024
Additional CPE details can be found here.
Respiratory syncytial virus (RSV) is a leading cause of pneumonia and hospitalizations in children and older adults. A search for a vaccine may finally be over. Join host, Geoff Wall, and guest, Jake Galdo, as they dive into part 2 of a two-part series examining new research on the proposed RSV vaccine.
The GameChanger
RSV, COVID-19, and influenza are major disease burdens on children and older adults. Fortunately, COVID-19 and influenza have widely available vaccines – and maybe soon for RSV. A recent study of the mRNA vaccine in pregnant patients may help newborns.
Show Segments
00:00 - Introductions
02:57 - Recap From Part 1
06:45 - Looking at the MATISSE Study
14:17 - The GameChanger: MATISSE Results
22:27 - Connecting to Practice: Barriers to Applying
31:05 - Closing Remarks
Host
Geoff Wall, PharmD, BCPS, FCCP, BCGP
Professor of Pharmacy Practice, Drake University
Internal Medicine/Critical Care, UnityPoint Health
Guest
Jake Galdo, PharmD, MBA, BCPS, BCGP
Managing Network Facilitator, CPESN Health Equity
CEO, Seguridad
Reference
Kampmann B, Madhi SA, Munjal I, et al. Bivalent Prefusion F Vaccine in Pregnancy to Prevent RSV Illness in Infants. N Engl J Med. 2023 Apr 20;388(16):1451-1464. doi: 10.1056/NEJMoa2216480. Epub 2023 Apr 5. PMID: 37018474.
Pharmacist Members, REDEEM YOUR CPE HERE!
Not a member? Get a Pharmacist Membership & earn CE for GameChangers Podcast episodes! (30 mins/episode)
CE Information
Learning Objectives
Upon successful completion of this knowledge-based activity, participants should be able to:
1. Discuss the MATISSE study in relation to RSV vaccines
2. Describe barriers to applying the information in this study to general populations
0.05 CEU/0.5 Hr
UAN: 0107-0000-23-193-H06-P
Initial release date: 05/08/2023
Expiration date: 05/08/2024
Additional CPE details can be found here.
Previous Episode
The Novel RSV Vaccine: Part 1
Respiratory syncytial virus (RSV) is a leading cause of pneumonia and hospitalizations in children and older adults. A search for a vaccine may finally be over. Join host, Geoff Wall, and guest, Jake Galdo, as they dive into part 1 of a two-part series examining new research on the proposed RSV vaccine.
The GameChanger
RSV, COVID-19, and influenza are major disease burdens on children and older adults. Fortunately, COVID-19 and influenza have widely available vaccines – and maybe soon for RSV. A recent study of the mRNA vaccine in older adults improves antibody titers.
Show Segments
00:00 - Introductions
03:06 - Barriers to Development of the RSV Vaccine
06:46 - Looking at the RSV Vaccine Study
13:01 - The GameChanger: The Vaccine Outcomes
20:57 - Connecting to Practice: The Potential Future of This Vaccine
28:19 - Closing Remarks
Host
Geoff Wall, PharmD, BCPS, FCCP, BCGP
Professor of Pharmacy Practice, Drake University
Internal Medicine/Critical Care, UnityPoint Health
Guest
Jake Galdo, PharmD, MBA, BCPS, BCGP
Managing Network Facilitator, CPESN Health Equity
CEO, Seguridad
References and Resources
Falsey AR, Hennessey PA, Formica MA, Cox C, Walsh EE. Respiratory syncytial virus infection in elderly and high-risk adults. N Engl J Med. 2005 Apr 28;352(17):1749-59. doi: 10.1056/NEJMoa043951. PMID: 15858184.
Pharmacist Members, REDEEM YOUR CPE HERE!
Not a member? Get a Pharmacist Membership & earn CE for GameChangers Podcast episodes! (30 mins/episode)
CE Information
Learning Objectives
Upon successful completion of this knowledge-based activity, participants should be able to:
1. Describe barriers to development of an RSV vaccine
2. Discuss outcomes of an RSV vaccines in older adults
0.05 CEU/0.5 Hr
UAN: 0107-0000-23-192-H06-P
Initial release date: 05/01/2023
Expiration date: 05/01/2024
Next Episode
Personalized Treatment for Hypertension?
About 50% of Americans have hypertension, yet WHICH is a preferred anti-hypertensive strategy is a random process. And pharmacogenomics may not be needed. Join host, Geoff Wall, as he evaluates a recent study evaluating the role of personalized medication selection for persons with hypertension.
The GameChanger
Although no genetic markers exist to determine optimal hypertensive pharmacotherapy, initial and secondary hypertensive therapy does impact outcomes. A personalized approach does produce a greater reduction in blood pressure.
Host
Geoff Wall, PharmD, BCPS, FCCP, BCGP
Professor of Pharmacy Practice, Drake University
Internal Medicine/Critical Care, UnityPoint Health
Reference
Sundström J, Lind L, Nowrouzi S, et al. Heterogeneity in Blood Pressure Response to 4 Antihypertensive Drugs: A Randomized Clinical Trial. JAMA. 2023;329(14):1160–1169. doi:10.1001/jama.2023.3322
Pharmacist Members, REDEEM YOUR CPE HERE!
Not a member? Get a Pharmacist Membership & earn CE for GameChangers Podcast episodes! (30 mins/episode)
CE Information
Learning Objectives
Upon successful completion of this knowledge-based activity, participants should be able to:
1. Describe the results of the PHYSIC study
2. Discuss the limitations of the PHYSIC study
0.05 CEU/0.5 Hr
UAN: 0107-0000-23-205-H01-P
Initial release date: 5/22/2023
Expiration date: 5/22/2024
Additional CPE details can be found here.
If you like this episode you’ll love
Episode Comments
Generate a badge
Get a badge for your website that links back to this episode
<a href="https://goodpods.com/podcasts/ceimpact-podcast-385948/the-novel-rsv-vaccine-part-2-54918369"> <img src="https://storage.googleapis.com/goodpods-images-bucket/badges/generic-badge-1.svg" alt="listen to the novel rsv vaccine: part 2 on goodpods" style="width: 225px" /> </a>
Copy